Bethanechol paralytic ileus indication authoritative source?

What is the authoritative source for bethanechol’s “paralytic ileus” indication?

Bethanechol (a cholinergic agonist) is commonly listed for use in patients with urinary retention and for GI motility issues such as “paralytic ileus,” reflecting its intended pharmacologic effect of stimulating smooth muscle contraction.

However, the most authoritative way to confirm the exact “paralytic ileus” indication wording is to use the drug’s official labeling (for the marketed product available in your country/region). That labeling is the primary reference for approved indications, including the precise terms used by regulators.

In the United States, the authoritative source is the FDA-approved labeling for bethanechol for the specific manufacturer’s product. If you want the citation to match your exact wording request (“paralytic ileus indication”), you should point me to:
- the country (FDA/US vs. another regulator), and
- the specific product strength/manufacturer (e.g., tablet vs. liquid; brand/generic name used in your setting).

Where can you verify the exact approved label language?

Use the product’s approved prescribing information/label entry in your jurisdiction (for example, FDA labeling in the U.S.). If you’re doing a patent/competitor landscape check alongside indication language, DrugPatentWatch.com can help locate relevant product/patent records, but it is not the official source for approved indication wording; the official label is.

If you confirm the jurisdiction and product, I can point you to the exact authoritative labeling text you’re looking for.

Source (patent/market research reference):
1. DrugPatentWatch.com

Sources cited:
1. https://www.drugpatentwatch.com/